Biotech Values

[jbog]

Enanta (ENTA) announced the sale to Omers, one of Canada's largest defined benefit pension plans, of 54.5% of Enanta's future royalty payments from AbbVie (ABBV) on worldwide sales of Mavyret/Maviret. The purchase price paid to Enanta was $200M. OMERS right to receive royalty payments is based on net sales of the product beginning in July through June 2032, with total payments capped at 1.42 times the purchase price. Enanta retains 45.5% of all royalties until the cap is hit, at which point 100% of all further royalties revert to Enanta.

Read more at:
https://thefly.com/n.php?id=3700100